Skip to content

High-density Flexible μECoG for Epilepsy Surgery - A Single-Arm ECT

Precision Resection of the Epileptogenic Zone Using Intraoperative Submillimeter Micro-Electrocorticography (Epi-PRECISE): A Single-Arm Trial With an External Historical Control Cohort

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07656857
Acronym
Epi-PRECISE
Enrollment
85
Registered
2026-06-18
Start date
2026-09-01
Completion date
2028-12-31
Last updated
2026-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Focal Epilepsy, Intraoperative Monitoring

Keywords

Epilepsy surgery, microelectrocorticography (μECoG)

Brief summary

What's the clinical value of high-density flexible microelectrocorticography (μECoG) for guiding the resection of epileptogenic zone (EZ) in epilepsy surgery?

Detailed description

1. Compare the effect of intraoperative high-density flexible μECoG guidance versus no intraoperative μECoG guidance on surgical prognosis in patients with drug-resistant focal epilepsy. 2. Explore intraoperative electrophysiological biomarkers recorded by high-density μECoG that are associated with surgical prognosis.

Interventions

DEVICEUsing High-density Flexible microElectrocorticography for intraoperative monitoring

During resective epilepsy surgery, a sterile high-density flexible microelectrocorticography will be placed on the exposed cortical surface over the suspected epileptogenic zone and adjacent cortex. The array will be used for high-spatial-resolution intraoperative μECoG recording and real-time analysis of epileptiform activity, including interictal spikes, high-frequency oscillations, spatial discharge gradients, and propagation patterns. The intraoperative ECoG findings will be provided to the surgical team to assist in defining the epileptogenic zone and tailoring the extent of resection. The high-density μECoG is used for intraoperative recording only and will be removed before wound closure.

Sponsors

Beijing Tiantan Hospital
Lead SponsorOTHER
Beijing Fengtai Hospital
CollaboratorUNKNOWN
Peking University First Hospital
CollaboratorOTHER
The Chinese University of Hong Kong, Shenzhen
CollaboratorOTHER
Beijing Xinzhida Neural Technology Co., Ltd
CollaboratorUNKNOWN
Beijing Neurosurgical Institute
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Masking description

Outcome assessors will be blinded to group allocation when evaluating postoperative seizure outcomes. Due to the surgical nature of the intervention, participants, care providers, and investigators cannot be masked.

Eligibility

Sex/Gender
ALL
Age
3 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Age 3 to 60 years. 2. Diagnosis of drug-resistant epilepsy, defined as persistent seizures despite treatment with two or more appropriately selected, adequately dosed and adequately tried antiseizure medications. 3. Diagnosis of focal epilepsy after standard presurgical evaluation and considered suitable for resective epilepsy surgery. 4. Preoperative cognitive or developmental status sufficient to participate in study assessments, as judged by the investigator and assessed using age-appropriate validated instruments. For participants aged 3 to 6 years, developmental status must be within the normal range according to the Griffiths Mental Development Scales. For participants aged 6 to 16 years, cognitive function must be within the normal range according to the Wechsler Intelligence Scale for Children. For participants older than 16 years, a Mini-Mental State Examination score of 24 or higher will be required. 5. Written informed consent provided by the participant or, when applicable, by a legal guardian.

Exclusion criteria

1. Suspected mesial temporal lobe epilepsy after multidisciplinary presurgical evaluation. 2. History of any previous neurosurgical craniotomy before epilepsy surgery. 3. Severe psychiatric, cognitive, or psychological disorder that prevents participation in the study or completion of follow-up. 4. Contraindication to surgery.

Design outcomes

Primary

MeasureTime frameDescription
Seizure Freedom Rate at 6 Months After SurgeryFrom surgery to 6 months postoperativelyThe proportion of participants who remain free from any type of epileptic seizure during the 6-month postoperative follow-up period.

Secondary

MeasureTime frameDescription
Seizure Freedom Rate at 1 Year After SurgeryFrom surgery to 1 year postoperativelyThe proportion of participants who remain free from any type of epileptic seizure during the 1-year postoperative follow-up period.
Postoperative Seizure Outcome According to ILAE Classification6 months and 1 year postoperativelyPostoperative seizure outcome will be evaluated using the International League Against Epilepsy classification at 6 months and 1 year after surgery. ILAE class 1 indicates complete seizure freedom without aura, and higher classes indicate worse seizure outcomes.
Monthly Seizure FrequencyBaseline, 6 months postoperatively, and 1 year postoperativelyMonthly seizure frequency will be assessed before surgery and at 6 months and 1 year after surgery. The measure is defined as the average number of epileptic seizures per month.
Seizure Severity Assessed by the National Hospital Seizure Severity ScaleBaseline, 6 months postoperatively, and 1 year postoperativelySeizure severity will be assessed using the National Hospital Seizure Severity Scale (NHS3) before surgery and at 6 months and 1 year after surgery. The NHS3 is a seizure severity scale with scores ranging from 1 to 27, with higher scores indicating more severe seizures and therefore a worse outcome.
Developmental Function Assessed by the Griffiths Mental Development ScalesBaseline, 6 months postoperatively, and 1 year postoperativelyFor participants aged 3 to 6 years, developmental function will be evaluated using the Griffiths Mental Development Scales before surgery and at 6 months and 1 year after surgery. The primary reported score will be the General Developmental Quotient or General Quotient. The quotient score ranges from 50 to 150, with higher scores indicating better developmental function and therefore a better outcome.
Cognitive Function Assessed by the Wechsler Intelligence Scale for ChildrenBaseline, 6 months postoperatively, and 1 year postoperativelyFor participants aged 6 to 16 years, cognitive function will be evaluated using the Wechsler Intelligence Scale for Children before surgery and at 6 months and 1 year after surgery. The primary reported score will be the Full Scale Intelligence Quotient. The Full Scale Intelligence Quotient standard score ranges from 40 to 160, with higher scores indicating better cognitive function and therefore a better outcome.
Cognitive Function Assessed by the Mini-Mental State ExaminationBaseline, 6 months postoperatively, and 1 year postoperativelyFor participants older than 16 years, cognitive function will be evaluated using the Mini-Mental State Examination (MMSE) before surgery and at 6 months and 1 year after surgery. The MMSE total score ranges from 0 to 30, with higher scores indicating better cognitive function and therefore a better outcome.
Quality of Life Assessed by the Quality of Life in Epilepsy Inventory-31 or the Pediatric Quality of Life Inventory Version 4.0Baseline, 6 months postoperatively, and 1 year postoperativelyQuality of life will be evaluated before surgery and at 6 months and 1 year after surgery. Adult participants will be assessed using the Quality of Life in Epilepsy Inventory-31 (QOLIE-31), and pediatric participants will be assessed using the Pediatric Quality of Life Inventory Version 4.0 (PedsQL 4.0). Both scales are transformed to scores ranging from 0 to 100, with higher scores indicating better quality of life and therefore a better outcome.
Postoperative ComplicationsPerioperative period, 6 months postoperatively, and 1 year postoperativelyThe incidence of postoperative complications, including infection, fever, neurological deficits, and other surgery-related complications, will be recorded during the perioperative period and postoperative follow-up.
Surgery-Related Adverse EventsPerioperative periodThe incidence of surgery-related adverse events will be recorded during the perioperative period. Adverse events include events directly related to the surgical procedure.
Serious Adverse EventsPerioperative periodThe incidence of serious adverse events, including postoperative death or severe deterioration of health status during the perioperative period, will be recorded.

Countries

China

Contacts

CONTACTKai Zhang Dr
zhangkai62035@sina.com86 01059975051

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 14, 2026